Phase II trial of bevacizumab (A), lenalidomide (R), docetaxel (D), and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
Xuan Huang
No relevant relationships to disclose
Yangmin M. Ning
No relevant relationships to disclose
James L. Gulley
No relevant relationships to disclose
Paul Gustav Kluetz
No relevant relationships to disclose
David Adelberg
No relevant relationships to disclose
Marcia Mulquin
No relevant relationships to disclose
Ravi A. Madan
No relevant relationships to disclose
Carol Bassim
No relevant relationships to disclose
William D. Figg
No relevant relationships to disclose
William L. Dahut
No relevant relationships to disclose